INITIAL ASSESSMENT OF REAL-WORLD USAGE OF EXTENDED-RELEASE INJECTABLE PALIPERIDONE PALMITATE AMONG MEDICAID INSURED SCHIZOPHRENIA PATIENTS

被引：0
|
作者：
Kamat, S. [1 ]
Gutierrez, B. [1 ]
Eramo, A. [2 ]
Zubek, D. [1 ]
Baker, R. A. [3 ]
Lin, J. [4 ]
Karson, C. [5 ]
机构：
[1] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[2] H Lundbeck & Co AS, Copenhagen, Denmark
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[4] Novosys Hlth, Flemington, NJ USA
[5] CNK Consulting, Wayne, PA USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1580
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A61 / A61
页数：1
相关论文
共 50 条
  • [31] Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
    Taro Kishi
    Kenji Sakuma
    Nakao Iwata
    Translational Psychiatry, 12
  • [32] Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
    Jung, Seung-Ho
    Yoon, Jin-Sang
    Ahn, Yong-Min
    Kim, Yong-Sik
    Kim, Chul-Eung
    PSYCHIATRY INVESTIGATION, 2013, 10 (04) : 407 - 416
  • [33] Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
    Jariyavilas, Apichat
    Thavichachart, Nuntika
    Kongsakon, Ronnachai
    Chantakarn, Sunanta
    Arunpongpaisal, Suwanna
    Chantarasak, Vasu
    Jaroensook, Piyadit
    Kittiwattanagul, Khanogwan
    Nerapusee, Osot
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 141 - 146
  • [34] Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia A Real-World Multicenter, Retrospective, Mirror-Image Study
    Devrimci-Ozguven, Halise
    Atmaca, Murad
    Baran, Zeynep
    Cengisiz, Cengiz
    Cinar, Cem
    Erol, Atila
    Genc, Yasin
    Karadag, Hasan
    Karakulah, Kamuran
    Karasu, Umut
    Kaya, Mehmet Cenral
    Kizil, Emre
    Ozcan, Halil
    Tiryaki, Ahmet
    Ucok, Alp
    Varlik, Cenk
    Yazar, Sila Menekse
    Yildiz, Mesut
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 604 - 610
  • [35] Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
    Markovic, M.
    EUROPEAN PSYCHIATRY, 2022, 65 : S728 - S728
  • [36] Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
    Pesa J.A.
    Muser E.
    Montejano L.B.
    Smith D.M.
    Meyers O.I.
    Drugs - Real World Outcomes, 2015, 2 (4) : 377 - 385
  • [37] Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits
    Joshi, Kruti
    Lafeuille, Marie-Helene
    Kamstra, Rhiannon
    Tiggelaar, Sean
    Lefebvre, Patrick
    Kim, Edward
    Yue, Yong
    Tandon, Neeta
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (02) : 121 - 133
  • [38] Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in South Korea
    Shin, Wonsuk
    Lee, Dong Hyeon
    Kim, Min-Kyoung
    Lee, Sang-Hyuk
    Cho, Doo-Yeoun
    Bang, Minji
    EARLY INTERVENTION IN PSYCHIATRY, 2021, 15 (06) : 1759 - 1767
  • [39] "Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients
    Ferraro, Vincent
    Lafreniere, Simon
    Demers, Marie-France
    Roy, Marc-Andre
    Abdel-Baki, Amal
    PSYCHOPHARMACOLOGY, 2020, 237 (12) : 3795 - 3797
  • [40] Long-term metabolic outcomes of oral paliperidone extended-release treatment in patients with schizophrenia
    Kramer, Michelle
    Eerdekens, Marielle
    Lane, Rosanne
    Lim, Pilar
    Sherr, Jay
    Palumbo, Joseph
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 258S - 258S
12345